These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 28819011)
1. Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011 [TBL] [Abstract][Full Text] [Related]
2. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Delfau-Larue MH; Klapper W; Berger F; Jardin F; Briere J; Salles G; Casasnovas O; Feugier P; Haioun C; Ribrag V; Thieblemont C; Unterhalt M; Dreyling M; Macintyre E; Pott C; Hermine O; Hoster E; Blood; 2015 Jul; 126(5):604-11. PubMed ID: 26022239 [TBL] [Abstract][Full Text] [Related]
3. TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage. Dong HJ; Zhou LT; Fang C; Fan L; Zhu DX; Wang YH; Li JY; Xu W Med Oncol; 2012 Sep; 29(3):2166-73. PubMed ID: 22057359 [TBL] [Abstract][Full Text] [Related]
5. Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. Dahl M; Husby S; Eskelund CW; Besenbacher S; Fjelstrup S; Côme C; Ek S; Kolstad A; Räty R; Jerkeman M; Geisler CH; Kjems J; Kristensen LS; Grønbæk K Leukemia; 2022 Jan; 36(1):177-188. PubMed ID: 34244612 [TBL] [Abstract][Full Text] [Related]
6. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas. Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679 [TBL] [Abstract][Full Text] [Related]
8. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management. Vose JM Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091 [TBL] [Abstract][Full Text] [Related]
9. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study. Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350 [TBL] [Abstract][Full Text] [Related]
10. The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy. Holte H; Beiske K; Boyle M; Trøen G; Blaker YN; Myklebust J; Kvaløy S; Rosenwald A; Lingjaerde OC; Rimsza LM; Smeland EB; Scott DW; Kolstad A Br J Haematol; 2018 Oct; 183(2):225-234. PubMed ID: 30080252 [TBL] [Abstract][Full Text] [Related]
11. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Aukema SM; Hoster E; Rosenwald A; Canoni D; Delfau-Larue MH; Rymkiewicz G; Thorns C; Hartmann S; Kluin-Nelemans H; Hermine O; Dreyling M; Klapper W Blood; 2018 Jan; 131(4):417-420. PubMed ID: 29196411 [TBL] [Abstract][Full Text] [Related]
12. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma. Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365 [TBL] [Abstract][Full Text] [Related]
13. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Vose JM Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436 [TBL] [Abstract][Full Text] [Related]
14. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study. Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542 [TBL] [Abstract][Full Text] [Related]
15. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Geisler CH; Kolstad A; Laurell A; Jerkeman M; Räty R; Andersen NS; Pedersen LB; Eriksson M; Nordström M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Brown P; Elonen E; Br J Haematol; 2012 Aug; 158(3):355-62. PubMed ID: 22640180 [TBL] [Abstract][Full Text] [Related]